COMMUNIQUÉS West-GlobeNewswire

Seer to Participate in Upcoming November Investor Conferences

08/11/2024 - 13:00

REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be [...]

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

08/11/2024 - 13:00

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, [...]

Apyx Medical Corporation Announces $7,000,000 Million Registered Direct Offering

08/11/2024 - 13:05

CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology [...]

Cartesian Therapeutics Announces New Employment Inducement Grants

08/11/2024 - 13:05

FREDERICK, Md., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune [...]

Notification of managers’ transactions

08/11/2024 - 13:27

ANNOUNCEMENT NO. 283 8 November 2024 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in [...]

Notification of managers’ transactions

08/11/2024 - 13:28

ANNOUNCEMENT NO. 284 8 November 2024 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in [...]

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

08/11/2024 - 13:30

Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to enable interim analysis, with guidance for trial size adaptation or futility expected by the end of 2Q 2025 InflaRx [...]

Pearson Medical Technologies Introduces m:Print Bar Code Labeling Software v4 for Pharmacy Drug Supply Chain Security Act (DSCSA) Compliance

08/11/2024 - 13:45

ALEXANDRIA, La., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Pearson Medical Technologies announces the international release of m:Print® Bar Code Labeling Software Version 4 , a powerful new upgrade of its industry-leading [...]

BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

08/11/2024 - 13:50

BriaCell’s clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust anti-cancer activity in preclinical models Novel therapy activates both innate and [...]

Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

08/11/2024 - 14:00

BOSTON and LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces [...]

Humacyte Third Quarter 2024 Financial Results and Business Update

08/11/2024 - 14:00

- FDA review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma is ongoing - - Results from the V007 Phase 3 clinical trial of the ATEV in arteriovenous (AV) access for hemodialysis [...]

Spectral Medical Announces Third Quarter Results and Provides Corporate Update

08/11/2024 - 14:00

Tigris Trial Enrollment at 135 Patients Strengthened Balance Sheet with Expected Funds to Complete Tigris Trial Enrollment TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) ( [...]

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

08/11/2024 - 14:00

In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare Disease Two Novel Radiopharma Clinical Trials now Active and Enrolling Patients with Advanced Solid Cancers WILMETTE, Ill [...]

Vera Therapeutics to Participate at Upcoming Investor Conferences

08/11/2024 - 14:00

BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients [...]

Rapid Micro Biosystems to Participate in the Stifel 2024 Healthcare Conference

08/11/2024 - 14:00

LEXINGTON, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to [...]

Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.

08/11/2024 - 14:30

Facility significantly increases future financial and operational flexibility Up to $200M available, with $30 million drawn at close and additional $80 million available at Disc’s sole discretion through second-half [...]

ProPhase Labs Announces Pricing of Public Offering of Common Stock

08/11/2024 - 05:37

GARDEN CITY, NY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and diagnostics company, today announced the pricing of its [...]

Travere Therapeutics Announces Pricing of Public Offering of Common Stock

08/11/2024 - 03:05

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of $ [...]

CORRECTION - 23andMe to Report Q2 FY2025 Financial Results

07/11/2024 - 23:54

SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- An earlier release under the same headline should have noted 23andMe Holding Co. (Nasdaq: ME) (23andMe) will report financial results for the second quarter of fiscal [...]